Inovio Pharmaceuticals
104 hedge funds and large institutions have $24.5M invested in Inovio Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 20 closing their positions.
372% more call options, than puts
Call options by funds: $373K | Put options by funds: $79K
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
6% more funds holding
Funds holding: 98 → 104 (+6)
4.02% more ownership
Funds ownership: 33% → 37.02% (+4%)
51% less capital invested
Capital invested by funds: $49.5M → $24.5M (-$25.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$5.82M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.65M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.59M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$550K |
| 2 |
DM
Deerfield Management
New York
|
-$442K |
| 3 |
Renaissance Technologies
New York
|
-$393K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$379K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$228K |
INO Hedge Fund Activity: Q4 2024 in Review
104 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2024, worth a combined $24.5M — down 51% from $49.5M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new INO positions and 20 closed out — a net gain of 6 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $5.82M. The largest seller was Vanguard Group, cutting an estimated $550K.
- 104 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2024, up from 98 in Q3 2024.
- Funds reported $24.5M of Inovio Pharmaceuticals stock for Q4 2024, down 51% quarter-over-quarter.
- 26 funds opened new Inovio Pharmaceuticals positions in Q4 2024 and 20 closed out, a net change of +6 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2024 was Deep Track Capital, an estimated $5.82M added.
- The largest Inovio Pharmaceuticals seller in Q4 2024 was Vanguard Group, an estimated $550K sold.
Based on aggregated 13F filings for Q4 2024.